低剂量氯胺酮输注促进慢性非癌痛合并阿片使用障碍患者阿片减量:历史性队列研究
本研究为历史性队列研究,纳入59例长期使用阿片类药物且合并阿片使用障碍的慢性疼痛患者,这些患者门诊渐进减量失败。在5天住院期间给予低剂量氯胺酮输注以启动减量,结果显示阿片日剂量从基线207 mg MME显著降至出院时92 mg MME,并维持至12个月,耐受性良好。
要点
- 低剂量氯胺酮输注可帮助慢性疼痛合并阿片使用障碍患者启动并维持阿片减量。
- 5天住院期间低剂量氯胺酮输注后,68%患者实现即刻减量超过50%。
- 氯胺酮耐受性良好,患者未出现明显戒断症状。
核心结论
- 5天住院期间低剂量氯胺酮输注似乎有助于长期使用阿片类药物的慢性疼痛合并阿片使用障碍患者进行阿片减量。
研究设计与样本
- 历史性队列研究,使用2014年1月1日至2019年12月31日的医疗记录。
- 纳入59例长期使用阿片类药物、合并阿片使用障碍且门诊渐进减量失败的慢性疼痛患者。
- 在5天住院期间给予低剂量氯胺酮输注以启动减量。
主要发现
- 基线阿片日剂量为207 mg(±128)吗啡毫克当量(MME)。
- 出院时阿片日剂量降至92±72 mg MME(p<0.001)。
- 3个月时阿片日剂量为99±77 mg(p<0.001),12个月时为103±106 mg。
- 40例患者(68%)实现即刻减量超过50%,7例患者(12%)实现即刻停用。
- 17例患者失访。
临床怎么用
- 对于门诊渐进减量失败的慢性疼痛合并阿片使用障碍患者,可考虑5天住院低剂量氯胺酮输注辅助阿片减量。
局限性
- 本研究为历史性队列研究,需要前瞻性和对照研究来确认 findings。
- 17例患者失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term opioid use is associated with pharmacological tolerance, a risk of misuse and hyperalgesia in patients with chronic pain (CP). Tapering is challenging in this context, particularly with comorbid opioid-use disorder (OUD). The antihyperalgesic effect of ketamine, through N-methyl-D-aspartate (NMDA) antagonism, could be useful. We aimed to describe the changes in the dose of opioids consumed over 1 year after a 5-day hospitalisation with ketamine infusion for CP patients with OUD. METHODS: We performed a historical cohort study using a medical chart from 1 January 2014 to 31 December 2019. Patients were long-term opioid users with OUD and CP, followed by the Pain Center of the University Hospital of Toulouse, for which outpatient progressive tapering failed. Ketamine was administered at a low dose to initiate tapering during a 5-day hospitalisation. RESULTS: 59 patients were included, with 64% of them female and a mean age of 48±10 years old. The most frequent CP aetiologies were back pain (53%) and fibromyalgia (17%). The baseline opioid daily dose was 207 mg (±128) morphine milligram equivalent (MME). It was lowered to 92±72 mg MME at discharge (p<0.001), 99±77 mg at 3 months (p<0.001) and 103±106 mg at 12 months. More than 50% tapering was achieved immediately for 40 patients (68%), with immediate cessation for seven patients (12%). 17 patients were lost to follow-up. CONCLUSIONS: A 5-day hospitalisation with a low-dose ketamine infusion appeared useful to facilitate opioid tapering in long-term opioid users with CP and OUD. Ketamine was well tolerated, and patients did not present significant withdrawal symptoms. Prospective and comparative studies are needed to confirm our findings.
引用
- Elyn A, Roussin A, Lestrade C, et al. Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study. Reg Anesth Pain Med. 2025. PMID: 38499357. doi:10.1136/rapm-2023-105035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。